IMPORTANCE: Mutations in the gene encoding parkin (PARK2) are the most common cause of autosomal recessive juvenile-onset and young-onset parkinsonism. The few available detailed neuropathologic reports suggest that homozygous and compound heterozygous parkin mutations are characterized by severe substantia nigra pars compacta neuronal loss. OBJECTIVE: To investigate whether parkin-linked parkinsonism is a different clinicopathologic entity to Parkinson disease (PD). DESIGN, SETTING, AND PARTICIPANTS: We describe the clinical, genetic, and neuropathologic findings of 5 unrelated cases of parkin disease and compare them with 5 pathologically confirmed PD cases and 4 control subjects. The PD control cases and normal control subjects were matched first for age at death then disease duration (PD only) for comparison. RESULTS: Presenting signs in the parkin disease cases were hand or leg tremor often combined with dystonia. Mean age at onset was 34 years; all cases were compound heterozygous for mutations of parkin. Freezing of gait, postural deformity, and motor fluctuations were common late features. No patients had any evidence of cognitive impairment or dementia. Neuronal counts in the substantia nigra pars compacta revealed that neuronal loss in the parkin cases was as severe as that seen in PD, but relative preservation of the dorsal tier was seen in comparison with PD (P = .04). Mild neuronal loss was identified in the locus coeruleus and dorsal motor nucleus of the vagus, but not in the nucleus basalis of Meynert, raphe nucleus, or other brain regions. Sparse Lewy bodies were identified in 2 cases (brainstem and cortex). CONCLUSIONS AND RELEVANCE: These findings support the notion that parkin disease is characterized by a more restricted morphologic abnormality than is found in PD, with predominantly ventral nigral degeneration and absent or rare Lewy bodies.
IMPORTANCE: Mutations in the gene encoding parkin (PARK2) are the most common cause of autosomal recessive juvenile-onset and young-onset parkinsonism. The few available detailed neuropathologic reports suggest that homozygous and compound heterozygous parkin mutations are characterized by severe substantia nigra pars compacta neuronal loss. OBJECTIVE: To investigate whether parkin-linked parkinsonism is a different clinicopathologic entity to Parkinson disease (PD). DESIGN, SETTING, AND PARTICIPANTS: We describe the clinical, genetic, and neuropathologic findings of 5 unrelated cases of parkin disease and compare them with 5 pathologically confirmed PD cases and 4 control subjects. The PD control cases and normal control subjects were matched first for age at death then disease duration (PD only) for comparison. RESULTS: Presenting signs in the parkin disease cases were hand or leg tremor often combined with dystonia. Mean age at onset was 34 years; all cases were compound heterozygous for mutations of parkin. Freezing of gait, postural deformity, and motor fluctuations were common late features. No patients had any evidence of cognitive impairment or dementia. Neuronal counts in the substantia nigra pars compacta revealed that neuronal loss in the parkin cases was as severe as that seen in PD, but relative preservation of the dorsal tier was seen in comparison with PD (P = .04). Mild neuronal loss was identified in the locus coeruleus and dorsal motor nucleus of the vagus, but not in the nucleus basalis of Meynert, raphe nucleus, or other brain regions. Sparse Lewy bodies were identified in 2 cases (brainstem and cortex). CONCLUSIONS AND RELEVANCE: These findings support the notion that parkin disease is characterized by a more restricted morphologic abnormality than is found in PD, with predominantly ventral nigral degeneration and absent or rare Lewy bodies.
Authors: W C Nichols; N Pankratz; S K Uniacke; M W Pauciulo; C Halter; A Rudolph; P M Conneally; T Foroud Journal: J Med Genet Date: 2002-07 Impact factor: 6.318
Authors: Y Yamamura; S Kuzuhara; K Kondo; T Yanagi; M Uchida; H Matsumine; Y Mizuno Journal: Parkinsonism Relat Disord Date: 1998-08 Impact factor: 4.891
Authors: Peter P Pramstaller; Michael G Schlossmacher; Thomas S Jacques; Francesco Scaravilli; Cordula Eskelson; Imelda Pepivani; Katja Hedrich; Susanna Adel; Melissa Gonzales-McNeal; Rüdiger Hilker; Patricia L Kramer; Christine Klein Journal: Ann Neurol Date: 2005-09 Impact factor: 10.422
Authors: Christine Klein; Katja Lohmann-Hedrich; Ekaterina Rogaeva; Michael G Schlossmacher; Anthony E Lang Journal: Lancet Neurol Date: 2007-07 Impact factor: 44.182
Authors: Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder Journal: Mov Disord Date: 2014-11-12 Impact factor: 10.338
Authors: Fabienne C Fiesel; Thomas R Caulfield; Elisabeth L Moussaud-Lamodière; Kotaro Ogaki; Daniel F A R Dourado; Samuel C Flores; Owen A Ross; Wolfdieter Springer Journal: Hum Mutat Date: 2015-06-03 Impact factor: 4.878
Authors: Mario R Cornejo-Olivas; Luis Torres; Ignacio F Mata; Pilar Mazzetti; Diana Rivas; Carlos Cosentino; Miguel Inca-Martinez; Juan M Cuba; Cyrus P Zabetian; James B Leverenz Journal: Parkinsonism Relat Disord Date: 2015-01-15 Impact factor: 4.891
Authors: Lorraine V Kalia; Anthony E Lang; Lili-Naz Hazrati; Shinsuke Fujioka; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross; Vivianna M Van Deerlin; John Q Trojanowski; Howard I Hurtig; Roy N Alcalay; Karen S Marder; Lorraine N Clark; Carles Gaig; Eduardo Tolosa; Javier Ruiz-Martínez; Jose F Marti-Masso; Isidre Ferrer; Adolfo López de Munain; Samuel M Goldman; Birgitt Schüle; J William Langston; Jan O Aasly; Maria T Giordana; Vincenzo Bonifati; Andreas Puschmann; Margherita Canesi; Gianni Pezzoli; Andre Maues De Paula; Kazuko Hasegawa; Charles Duyckaerts; Alexis Brice; A Jon Stoessl; Connie Marras Journal: JAMA Neurol Date: 2015-01 Impact factor: 18.302
Authors: J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl Journal: Mov Disord Date: 2017-09 Impact factor: 10.338